Slingshot members are tracking this event:

Data for Phase 2 MONARCH 1 Trial of Abemaciclib Expected mid-2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Data from the phase 2 Monarch 1 trial of abemaciclib as a single-agent is expected mid-2016.  The trial studies abemaciclib for the treatment of squamous non-small cell lung cancer.
Additional Relevant Details we look forward to receiving the final MONARCH 2 results in the first half of 2017
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 03, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Monarch 1 Study, Phase 2 Trial, Abemaciclib, Single-agent, Non-small Cell Lung Cancer